322. Hemophilia A and B: Clinical and Epidemiological: Poster II
0 activities
Assessment of Bleeding Severity and Prevalence of Iron Deficiency Among Hemophilia B Carriers By Factor IX Activity Levels
1 activities
Assessment of Bleeding Severity and Prevalence of Iron Deficiency Among Hemophilia B Carriers By Factor IX Activity Levels
Become–9: A Phase 1/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B
1 activities
Become–9: A Phase 1/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B
Characterizing an Underdiagnosed Condition: Hemophilia in Females
1 activities
Characterizing an Underdiagnosed Condition: Hemophilia in Females
Circulating and Synovial Fluid Levels of YKL-40 Protein in Patients with Hemophilia and Arthropathy: Preliminary Observations
1 activities
Circulating and Synovial Fluid Levels of YKL-40 Protein in Patients with Hemophilia and Arthropathy: Preliminary Observations
Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a
1 activities
Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a
Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study
1 activities
Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study
FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A
1 activities
FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A
Indirect Comparison of the Efficacy and Therapy-Related Costs of a Pharmacokinetic and Individualized Prophylaxis Regimen with Simoctocog Alfa Versus Other Extended-Half Life Factor VIII Concentrates
1 activities
Indirect Comparison of the Efficacy and Therapy-Related Costs of a Pharmacokinetic and Individualized Prophylaxis Regimen with Simoctocog Alfa Versus Other Extended-Half Life Factor VIII Concentrates
Mechanistic Modeling to Support Hemostatic Equivalency of Antithrombin Lowering in People with Hemophilia A or B
1 activities
Mechanistic Modeling to Support Hemostatic Equivalency of Antithrombin Lowering in People with Hemophilia A or B
Patient and Caregiver Preferences for Hemophilia Prophylactic Treatments: A Discrete Choice Experiment
1 activities
Patient and Caregiver Preferences for Hemophilia Prophylactic Treatments: A Discrete Choice Experiment
Post?MarkPost‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients with Congenital Hemopeting Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients with Congenital Hemophilia A with Inhibitors
1 activities
Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients with Congenital Hemophilia A with Inhibitors
Real-World Data on Hemophilia a Patient Usage of Bay 81-8973 and Bay 94-9027 Stratified By Body Mass Index Categories in the Athndataset
1 activities
Real-World Data on Hemophilia a Patient Usage of Bay 81-8973 and Bay 94-9027 Stratified By Body Mass Index Categories in the Athndataset
Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study
1 activities
Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study